Retorin Suspension Use In Pregnancy & Lactation

Pregnancy: There are no adequate and well-controlled studies in pregnant women. However, observational studies in humans have reported cardiovascular malformation after exposure to medicinal products containing erythromycin during early pregnancy.
Erythromycin has been reported to cross the placental barrier in humans, but foetal plasma levels are generally low.
There have been reports that maternal macrolide antibiotics exposure within 7 weeks of delivery may be associated with a higher risk of infantile hypertrophic pyloric stenosis (IHPS).
Therefore, erythromycin should only be used during pregnancy if clinically needed and the benefit of treatment is expected to outweigh any small increased risks which may exist. The risk-benefit balance should be considered for each individual patient before prescribing erythromycin during pregnancy.
Breast-feeding: Erythromycins can be excreted into breast-milk. Caution should be exercised when administering erythromycin to lactating mothers due to reports of infantile hypertrophic pyloris stenosis in breast-fed infants.